NasdaqGM:KYMRBiotechs
Is Kymera Therapeutics (KYMR) Turning Its Immunology Pipeline Into a Durable Platform Advantage?
Kymera Therapeutics has outlined past and upcoming milestones across its oral immunology pipeline, including launching the BREADTH Phase 2b trial of KT-621 in eosinophilic asthma and reporting earlier positive Phase 1b data in atopic dermatitis.
The company’s expanded clinical agenda, together with progress on partnered programs such as the IRAK4 degrader with Sanofi and an option-based collaboration with Gilead, highlights growing external interest in its targeted protein degradation...